Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer
Steven J. Cohen(Abington Memorial Hospital), Neal J. Meropol(Flatiron Health (United States)), Hao Wang(University of Science and Technology of China), James C. Watson(Vanderbilt University), Ann Pellegrino(Fox Chase Cancer Center), Elin R. Sigurdson(Fox Chase Cancer Center), Shawn M. O'Hara(Eon Corporation (United States)), Louis M. Weiner(Georgetown University), R. Katherine Alpaugh(Fox Chase Cancer Center), Denis A. Smirnov(Eon Corporation (United States)), Maryann Bilbee(Fox Chase Cancer Center), Nancy Lewis(Tris Pharma (United States)), André Rogatko(Cedars-Sinai Medical Center), Steve Gross(Eon Corporation (United States)), John P. Hoffman(Fox Chase Cancer Center), W. Jeffrey Allard, Jonathan D. Cheng(Princeton University), Leon W.M.M. Terstappen(Düsseldorf University Hospital)
Cited by 189
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k